-
2025-521093-34-00
5
rare disease
-
2025-521199-80-00
4
Patients with previously untreated symptomatic chronic lymphocytic leu
-
2025-521322-14-00
4
Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation,
-
2025-521571-30-00
5
Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (
-
2025-521671-31-00
9
Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+)
-
2025-522511-42-00
4
Crohn's disease
-
2025-523149-80-00
10
Adult patients admitted to the ICU and receiving unplanned invasive me
-
2025-524297-42-00
5
CLTI defined as Rutherford category 4 or 5
-
2025-524573-16-00
6
Crohn's disease
-
2025-524697-42-00
5
Pleural infections
-
2025-524810-28-00
5
Acute Promyelocytic Leukemia
-
2024-514006-31-00
9
2026-04-16
Non-active Progressive Multiple Sclerosis (PMS)
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2022-501607-27-00
7
2026-01-06
Relapsed or refractory B-cell Non-Hodgkin lymphoma
-
2023-508995-12-01
4
2025-12-24
Recurrent or metastatic non-small cell lung cancer (NSCLC)
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2024-519496-26-00
10
2025-09-25
Intestinal Failure
-
2024-518973-32-00
5
2025-07-03
Chronic Graft-Versus-Host Disease
-
2024-513054-30-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2024-519113-59-00
4
2024-11-20
Hepatocellular carcinoma
-
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma